For Healthcare Professionals

Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive


About the study

The purpose of this study is evaluating Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive in Premenopausal Females Aged 14 to 35 Years (Inclusive).

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

  1. Postmenarcheal, premenopausal female aged 14 to 35 years (inclusive)
  2. At risk for pregnancy (including heterosexual vaginal intercourse at least once a month and not sterilized).
  3. No desire for pregnancy within 1 year following screening and is not intending to use any other form of contraception
  4. Good physical and mental health
  5. History of regular menstrual cycles prior to the use of any hormonal contraceptive.
  6. Able and willing to adhere study procedures


Exclusion Criteria:

  1. Current known or expected pregnancy
  2. History of subfertility or infertility
  3. Less than 2 normal menstrual cycles following recent pregnancy of gestational age
  4. Breastfeeding within 2 months of study drug start
  5. Known HIV infection
  6. Untreated gonorrhea, chlamydia, or trichomonas
  7. abnormal PAP within timeline of standard of care guidelines
  8. Unexplained/unresolved abnormal vaginal bleeding
  9. Presence/history of VTE, ATE, transient ischemic attack, angina pectoris, or claudication
  10. Higher risk for VTE
  11. Uncontrolled or severe hypertension
  12. Severe dyslipoproteinemia
  13. History of migraine with aura or focal neurological symptoms
  14. Diabetes mellitus (with either end-organ involvement or >20 years duration)
  15. Multiple cardiovascular risk factors
  16. History of pancreatitis associated with severe hypertriglyceridemia
  17. Presence/history of clinically significant liver disease
  18. History of malabsorptive surgical procedures
  19. History of malignancy in last 5 years
  20. Presence/history of meningioma
  21. Disease that may worsen under hormonal treatment
  22. Presence/history of severe depression (unless currently stable and asymptomatic)
  23. Known allergy/sensitivity to NOMAC-E2
  24. Drug or alcohol abuse/dependence in last 2 years
  25. Clinically relevant abnormal lab result at screening
  26. Expected use of other contraceptive medications or medications that induce liver enzymes during study
  27. Used another investigational drug within 2 months of study drug start
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.
Phone iconCall 561-862-7446Email iconEmail Study Center

Study’s details



Age (in years)

14 - 35


Phase 3

Participants needed


Est. Completion Date

Mar 31, 2024

Treatment type



Organon and Co identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.